Biogen에 대한 매도 수량은 투자자에게 Biogen의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Biogen (NASDAQ:BIIB) 주식, 공매도 수량 보고

Biogen

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Analyst Color

Biotech

Earnings

Large Cap

News

Guidance

Health Care

Analyst Ratings

Movers

Trading Ideas

General

BIIB

수요일 바이오젠(NASDAQ:BIIB)은 4분기 조정 주당순이익(EPS)이 $3.44로 17% 증가하여 컨센서스 3.35달러를 초과했다고 보고했다. 이 회사는 매출이 24.6억 달러로 전년 대비 2% 증가(환율 변동 제외)하고 3% 증가(보고 기준)하여 컨센서스 24.0억 달러를 초과했다고 보고했다.

바이오젠, 4분기 실적 상회, 분석가는 레켐비 확장, 2025년 전망에 초점

Global

ALLK

CSCO

JNPR

MSFT

ORCL

RBLX

SAGE

SMIN

TYO:5401

TYO:5481

ULCC

WELL

신규 블록 세이지 테라퓨틱스(NASDAQ:SAGE)는 주주들을 만족시키기 위한 &#34;전략적 대안&#34;을 공식적으로 탐색하고 있다. 이 과정에는 가능한 사업 결합부터 전면적인 매각까지 모든 것이 포함된다.

딜 디스패치: 세이지와 실버스가 매각 중, 미스터비스트가 틱톡을 위해 20억 달러를 확보

ABBV

LNTH

NGVT

NPSCY

RVNC

SANW

SLRX

TMUS

대통령 조 바이든은 백악관에서의 마지막 며칠 동안 비폭력 마약 범죄자 석방를 우선시했지만, 틱톡? 이제는 대통령 당선자 도널드 트럼프의 문제이다. AP 통신에 따르면, 바이든은 금지 조치를 시행할 의사가 없으며, 이는 그의 마지막 정식 근무일인 1월 19일에 발효되고 트럼프의 취임식 하루 전이다.

딜 디스패치: 바이든이 틱톡 금지를 트럼프에게 넘기고, 또 다른 유명 소매업체 파산

Biogen Inc

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Buy and lowers the price target from $298 to $265.

Price Target

Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $265

Needham analyst Ami Fadia reiterates Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Biogento Hold

On Wednesday,&nbsp;Biogen Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)&nbsp;reported fourth-quarter adjusted EPS of $3.44, up 17%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.35</a>.
The company reported sales of $2.46 billion, up 2% year over year on constant currency and 3% on a reported basis, beating the <a href="https://www.benzinga.com/general/biotech/25/02/43659412/biogen-warns-lower-2025-revenue-inks-rd-funding-pact-with-royalty-pharma-for-late-stage-lupus-asset" target="_blank" rel="noreferrer noopener">consensus of $2.40 billion</a>.
As part of ongoing pipeline prioritization efforts, Biogen has decided to discontinue further development of BIIB113 in early Alzheimer&#8217;s disease, BIIB094 in early Parkinson&#8217;s disease, BIIB101 in multiple system atrophy, and BIIB143 (cemdomespib) in diabetic peripheral neuropathic pain.
Biogen forecasts a full-year 2025 adjusted EPS of $15.25-$16.25&nbsp;versus a consensus of $16.34.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown</a>
Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.
Goldman Sachs analyst Salveen Richter notes that Biogen&#8217;s management expects to remain disciplined with regard to capital allocation, pointing to an interest in early-to-mid-stage deals in immunology, <a target="_blank" href="https://www.benzinga.com/quote/BIIB/analyst-ratings" rel="noreferrer noopener">rare diseases, and neurology</a>.
The analyst notes that while Goldman Sachs is mainly focused on Zurzuvae and Skyclarys, it is also watching for declines in the multiple sclerosis portfolio and Spinraza business. The main priority is how the company plans to counteract these losses through new product launches and business development.
Investors were especially concerned about the FY25 outlook compared to market expectations, particularly for Leqembi, and the company&#8217;s plans for mergers, acquisitions, and pipeline growth.
The analyst notes that for Leqembi&#8217;s rollout in early Alzheimer&#8217;s, the growth of infusion centers and more doctors prescribing it are major advantages. So far, Eli Lilly&#8217;s Kisunla has had little impact.
&#8220;We continue to watch market share vs. growth dynamics, and the extent to which the IV maintenance approval, the potential approvals of subcutaneous maintenance and induction, alongside the wider availability of blood-based biomarkers will drive launch momentum in 2025+,&#8221; Goldman Sachs analyst writes.
Price Action: BIIB stock is down 4.6% at $132.90 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43667099/crypto-for-a-cause-blackbaud-teams-up-with-the-giving-block-to-supercharge-nonprofit-donations" target="_blank" rel="noreferrer noopener">Crypto For A Cause: Blackbaud Teams Up With The Giving Block To Supercharge Nonprofit Donations</a></li>
</ul>
Photo: Tada Images/Shutterstock.com

Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by <a href="https://www.benzinga.com/government/regulations/25/02/43656846/inflation-rises-more-than-expected-in-january-chills-interest-rate-cut-hopes">midday trading in New York.</a>
The S&amp;P 500 was down 0.2%, while the Nasdaq 100 was flat, both rebounding from sharp declines following the January Consumer Price Index report. Small-cap stocks underperformed, with the Russell 2000 slipping 0.8%.
The headline CPI rose 3% year over year in January, surpassing both December's 2.9% reading and economist forecasts of 2.9%. On a monthly basis, inflation increased 0.5%, outpacing expectations of 0.3% and accelerating from December's 0.4% gain. This marked the fastest monthly inflation rate since August 2023.
Core inflation, which excludes food and energy, climbed to 3.3% year over year from 3.2% in December. On a monthly basis, core CPI increased 0.4%, exceeding estimates of 0.3% and doubling December's 0.2% rise.
Treasuries and interest rate markets reacted sharply to the inflation data. Traders scaled back expectations for Federal Reserve rate cuts, now projecting only one reduction by December 2025.
Treasury yields surged, reflecting heightened investor uncertainty. The 10-year Treasury yield jumped 10 basis points to 4.64%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 1%.
Despite rising Treasury yields and a stronger dollar, gold edged up 0.2% to $2,910 per ounce. Oil prices dropped 2% after reports that Donald Trump spoke with Russian President Vladimir Putin, fueling speculation about a potential ceasefire in Ukraine.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also rebounded from earlier session losses.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,688.40</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,056.85</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,411.00</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% down to $603.77.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.4% down to $444.41.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $528.09.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.8% to $224.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.4%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.2%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped more than 4% after the electric vehicle maker tumbled 6.3% on Tuesday, reaching oversold levels and extending its losing streak to five consecutive sessions.</li>
</ul>
Stocks reacting to company earnings reports included: 
<ul>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 15.7%</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): up 4.5%</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 5.6%</li>
<li>América Móvil, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>): down 1.4%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>): up 0.2%</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>): up 0.3%</li>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>): up 2.9%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): up 6.8%</li>
<li>Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>): down 10.2%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): up 2.2%</li>
<li>Chimera Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>): down 8.9%</li>
<li>Ryder System Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>): up 4.0%</li>
<li>Smurfit WestRock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>): down 5.8%</li>
<li>Sonic Automotive Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>): down 2.4%</li>
<li>Alkermes Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>): up 4.1%</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>): up 1.0%</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>): down 4.6%</li>
<li>Blackstone Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXMT#NYSE">BXMT</a>): up 2.8%</li>
<li>Camtek Ltd/Israel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>): up 1.5%</li>
<li>Chefs' Warehouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>): up 13.0%</li>
<li>Diebold Nixdorf Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>): down 3.2%</li>
<li>Dominion Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.6%</li>
<li>Exelon Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): up 0.4%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43663963/record-high-egg-prices-drive-inflation-higher-in-january">Record-High Egg Prices Drive Inflation Higher In January</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Commodities

Economics

Federal Reserve

Markets

Tech

ETFs

$BTC

ALKS

AVXL

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

GILD

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?

WIIM

Biogen shares are trading lower after the company issued FY25 adjusted EPS guidance below estimates.

On Wednesday,&nbsp;Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.35</a>.
The company&nbsp;<a target="_blank" href="https://investors.biogen.com/static-files/a4eadd7a-6e77-4110-8289-94816df02324" rel="noreferrer noopener">reported</a> sales of&nbsp;$2.46 billion, up 2% year over on constant currency and 3% on a reported basis, beating the consensus of $2.40 billion.
Multiple sclerosis revenue of $1.07 billion decreased by 8% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $415.4 million <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43635908/what-to-expect-from-alzheimers-drugmaker-biogens-q4-earnings-on-wednesday" rel="noreferrer noopener">from $464.7 million</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42973945/fda-to-review-under-the-skin-weekly-autoinjector-for-biogen-eisais-alzheimers-drug-leqembi" rel="noreferrer noopener">FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi</a>
Rare disease revenue&nbsp;increased&nbsp;13% year over year (up 15% on constant currency) to $535.3 million. Spinraza's revenue increased to $421.4 million from $412.6 million a year ago.
Revenues from Skyclarys, acquired via Reata acquisition, reached $102.2 million during the quarter.
In Alzheimer's disease, Biogen said Leqembi fourth quarter global in-market sales of approximately $87 million, including U.S. in-market sales of approximately $50 million, representing good continued sequential growth.
Postpartum depression drug Zurzuvae's fourth-quarter sales reached $22.9 million.
Guidance: Biogen forecasts a full year 2025 adjusted EPS of $15.25-$16.25&nbsp;versus a consensus of $16.34.
Revenue is expected to decline by a mid-single-digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis product revenues are expected to be partially offset by increases in revenue from product launches.
For 2025, as compared to 2024, Biogen expects the operating margin percentage to remain relatively flat.
The Fit for Growth program is expected to generate approximately $1 billion of gross savings and $800 million net of reinvestment by the end of 2025.
Since the program was initiated in 2023, approximately $400 million of net savings have been achieved, and Biogen expects to realize the balance by the end of 2025.
Biogen expects combined Non-GAAP R&amp;D and SG&amp;A expenses to total approximately $3.9 billion in 2025.
Royalty Pharma plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) agreed to provide Biogen with R&amp;D funding of up to $250 million for litifilimab for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Litifilimab is currently in Phase 3 trials for SLE and CLE, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43651925/royalty-pharma-announces-r-d-funding-collaboration-with-biogen" rel="noreferrer noopener">with results expected between 2026 and 2027</a>.
Price Action: BIIB stock is down 6.74% at $130&nbsp;at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43653157/johnson-johnson-explores-sale-of-stroke-device-maker-cerenovus-as-medtech-overhaul-accelerates" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Explores Sale of Stroke Device Maker Cerenovus As MedTech Overhaul Accelerates</a></li>
</ul>

Financing

Contracts

RPRX

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

<ul>
<li>Full year 2025 financial guidance: Non-GAAP diluted EPS expected between $15.25 and $16.25.</li>
<li>Expect full year 2025 total revenue to decline by a mid-single digit percentage at constant currency versus full year 2024</li>
</ul>

Biogen Forecasts FY2025 Adjusted EPS Of $15.25-$16.25 Versus Consensus Of $16.34

Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) reported quarterly earnings of $3.44 per share which beat the analyst consensus estimate of $3.35 by 2.69 percent. This is a 16.61 percent increase over earnings of $2.95 per share from the same period last year. The company reported quarterly sales of $2.46 billion which beat the analyst consensus estimate of $2.40 billion by 2.17 percent. This is a 2.89 percent increase over sales of $2.39 billion the same period last year.

Biogen Q4 2024 Adj EPS $3.44 Beats $3.35 Estimate, Sales $2.46B Beat $2.40B Estimate

Royalty Pharma Entered Into An Agreement With Biogen To Provide Research And Development Funding Of Up To $250M For Litifilimab, A First-in-class Investigational Drug Candidate In Phase 3 With Demonstrated Proof-of-concept In Both Systemic Lupus Erythematosus And Cutaneous Lupus Erythematosus

U.S. stock futures fell on Wednesday after a mixed close on Tuesday as Federal Reserve Chairman Jerome Powell began his two-day testimony in front of Congress. All benchmark indices were lower except the Russell 2000.
Traders await the inflation data today as economists and betting markets are predicting a modest inflation report for January, boosting investor optimism that price pressures are easing and the Federal Reserve may continue its path toward interest rate cuts.
The headline consumer price index is <a href="https://www.benzinga.com/25/02/43627524/economists-betting-markets-predict-benign-january-inflation-what-could-go-wrong-this-time">forecasted to remain</a> at 2.9% year-over-year, based on median economist predictions tracked by TradingEconomics. Monthly, inflation is expected to increase by 0.3%, a slight deceleration from December&#8217;s 0.4% rise. 
The 10-year Treasury yield stood at 4.54%, while the two-year yield was at 4.29%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 95.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.07%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.15%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.17%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.07%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) both experienced negative premarket trading on Wednesday. SPY fell 0.14% to $604.45, and QQQ declined 0.06% to $527.67, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Wall Street ended Tuesday&#8217;s session with a mixed performance as investors reacted to further tariff announcements and awaited key inflation figures.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares declined sharply following news of a partnership between Chinese electric vehicle maker BYD and AI firm DeepSeek to develop self-driving technology.
DoorDash Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) surged in after-hours after strong results. Marriott International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) tumbled 5.4% after missing first-quarter guidance expectations and Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) jumped 4.73% after beating expectations.
Federal Reserve Chair Powell began his two-day testimony before Congress, stating that the Fed is in no hurry to change interest rates and reiterated its stance of not commenting on trade policy.
Communication services, health care, and consumer discretionary sectors fell, while all other sectors rose on Tuesday.
The Dow rose 123 points or 0.28% to 44,593.65, the S&amp;P 500 was up 0.03% and closed at 6,068.50, and the Nasdaq Composite declined by 0.36% to 19,643.86. Russell 2000 Index fell 0.53% to 2,275.70.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.36%</td>
<td>19,643.86</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.03%</td>
<td>6,068.50</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.28%</td>
<td>44,593.65</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.53%</td>
<td>2,275.70</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Jurrien Timmer, the director of global macros at Fidelity Investments highlighted that strong bull markets tend to &#8220;roar back to life&#8221; after corrections.
He hinted that after the recent pull-back in the market caused by DeepSeek when just 17% of stocks were above their moving average, only 53% of stocks are now above their 50-day moving average. He termed it as a &#8220;weak recovery&#8221;.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 equal-weight index remains below its all-time high, and only 53% of stocks are above their 50-day moving average. It's a rather weak recovery from the recent 5% pullback, during which only 17% of stocks were above their moving average. Strong bull markets tend to roar… <a href="https://t.co/mAm351Szew">pic.twitter.com/mAm351Szew</a>
&mdash; Jurrien Timmer (@TimmerFidelity) <a href="https://twitter.com/TimmerFidelity/status/1889420825557938504?ref_src=twsrc%5Etfw">February 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
However, underscoring U.S. equity fund and exchange-traded fund flows Timmer said &#8220;Sentiment remains quite constructive.&#8221;
&#8220;The sentiment surveys are more two-sided, but investors seem to remain poised for a good year in the markets,&#8221; he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Sentiment remains quite constructive, at least as far as equity flows are concerned. The sentiment surveys are more two-sided, but investors seem to remain poised for a good year in the markets. <a href="https://t.co/rx9Q9zwrtC">pic.twitter.com/rx9Q9zwrtC</a>
&mdash; Jurrien Timmer (@TimmerFidelity) <a href="https://twitter.com/TimmerFidelity/status/1889420904691552541?ref_src=twsrc%5Etfw">February 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to the analysts at BlackRock, U.S. equities have proved resilient this year, though escalating trade tensions could keep the pressure on in the coming months.
&#8220;Resilient growth, solid corporate earnings, potential deregulation and the AI theme keep us upbeat. Q4 earnings growth has broadened as we expected, with S&amp;P 500 earnings excluding the &#8216;magnificent 7&#8217; stocks up about 5% from a year ago and the consensus eyeing a 10% rise this year, LSEG Datastream data show. We keep our tactical U.S. equity overweight yet watch for triggers for a change, such as earnings losing steam,&#8221; stated BlackRock&#8217;s weekly market note.
See Also:<a href="https://www.benzinga.com/money/how-to-trade-futures"> How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul>
<li>Core and headline consumer price index data for January will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Fed Chairman Powell&#8217;s testimony to Congress continues at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>Atlanta Fed President Raphael Bostic will speak at 2:00 p.m. and New York Fed President John Williams will speak again at 3:30 p.m., ET.</li>
</ul>
<ul>
<li>January&#8217;s monthly U.S. federal budget data will be out by 2:00 p.m., ET.</li>
</ul>
<ul>
<li>Fed Governor Christopher Waller will be speaking at 5:05 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) was up 0.38% in the premarket on Wednesday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report quarterly earnings of 93 cents per share on revenue of $97.19 billion.</li>
</ul>
<ul>
<li>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) rose 0.71% as Wall Street expects it to report quarterly earnings of 78 cents per share on revenue of $6.66 billion before the opening bell.</li>
</ul>
<ul>
<li> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) slipped 0.24% ahead of its earnings, which will be released after the closing bell. Analysts expect it to report quarterly earnings of 91 cents per share on revenue of $13.87 billion.</li>
</ul>
<ul>
<li>DoorDash Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) was up 6.58% after it beat fourth-quarter expectations on revenue and EPS front and clocked 42 million monthly active users with a record high order frequency.</li>
</ul>
<ul>
<li>Pitney Bowes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) jumped 8.81% after reporting better-than-expected earnings for its fourth quarter and naming Bob Gold as its new CFO.</li>
</ul>
<ul>
<li>Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) was down 6.15% after reporting worse-than-expected earnings for its fourth quarter and issuing a weak revenue guidance for the first quarter.</li>
</ul>
<ul>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) advanced 0.93%, Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 3.21%, Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) jumped 2.64% and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) was up 0.44% ahead of their earnings today.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.12% to hover around $72.50 per barrel.
The gold spot index was down by 0.51% to $2,883.52 per ounce. The Dollar Index was up 0.01% at 107.977 level.
Asian markets advanced on Wednesday except for India's S&amp;P BSE Sensex index. Australia's ASX 200, South Korea's Kospi, Japan's Nikkei 225, China's CSI 300, and Hong Kong's Hang Seng index advanced. European markets were also higher in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43649613/mark-zuckerbergs-meta-platforms-sees-meteoric-surge-over-17-amid-historic-18-day-winning-streak-heres-what-technical-analysis-indicate-amid-overbought-conditions">Meta Stock Surges 17.47% In 17 Days, Marking One Of Its Longest Winning Streaks—Analysts Say There&#8217;s Still Room For Double-Digit Growth For Mark Zuckerberg&#8217;s Company</a></li>
</ul>
Image Via Shutterstock

Asia

Government

Macro Notification

Market Summary

Regulations

Bonds

Futures

Pre-Market Outlook

DASH

HOOD

RDDT

US Stocks Set For A Cautious Start Ahead Of Inflation Data: Expert Says 'Strong Bull Markets Tend To Roar Back To Life After Corrections'

ACRE

AEIS

AEMD

ALCO

AMWL

ASND

ASPN

ATRC

AYTU

BROS

CGNX

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) will release its fourth-quarter financial results, before the opening bell, <a href="https://www.benzinga.com/quote/biib/earnings">on Wednesday, Feb. 12, 2025.</a>
Analysts expect the Cambridge, Massachusetts-based company to report quarterly earnings at $3.36 per share, up from $2.95 per share in the year-ago period. Biogen projects quarterly revenue of $2.42 billion, compared to $2.39 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Sage Therapeutics recently announced that its Board of Directors initiated a process to explore strategic alternatives and rejected the unsolicited, nonbinding proposal it received from Biogen for $7.22 per share.
Biogen shares fell 2.2% to close at $139.39 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Citigroup analyst Geoff Meacham maintained a Neutral rating and cut the price target from $190 to $160 on Jan. 28, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Mohit Bansal maintained an Equal-Weight rating and slashed the price target from $190 to $165 on Jan. 10, 2025. This analyst has an accuracy rate of 73%.</li>
<li>BMO Capital analyst Evan Seigerman downgraded the stock from Outperform to Market Perform and cut the price target from $230 to $164 on Dec. 20, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Needham analyst Ami Fadia downgraded the stock from Buy to Hold with a price target of $270 on Nov. 18, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Oppenheimer analyst Jay Olson maintained an Outperform rating and cut the price target from $270 to $255 on Oct. 31, 2024. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying BIIB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12032109/image-98-1024x572.png" alt="" class="wp-image-778054" style="width:505px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12032109/image-98-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12032109/image-98-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12032109/image-98-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/12032109/image-98.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a></li>
</ul>

Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Investors with a lot of money to spend have taken a bullish stance on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BIIB, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Biogen.
This isn't normal.
The overall sentiment of these big-money traders is split between 55% bullish and 22%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $634,880, and 5 are calls, for a total amount of $219,709.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $250.0 for Biogen during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Biogen's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biogen's whale activity within a strike price range from $130.0 to $250.0 in the last 30 days. 
<h3>Biogen Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739306736_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$11.0</td>
<td>$10.8</td>
<td>$10.9</td>
<td>$140.00</td>
<td>$492.6K</td>
<td align="right">289</td>
<td align="right">458</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$15.4</td>
<td>$15.1</td>
<td>$15.4</td>
<td>$160.00</td>
<td>$93.9K</td>
<td align="right">85</td>
<td align="right">102</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.2</td>
<td>$10.7</td>
<td>$10.8</td>
<td>$140.00</td>
<td>$54.0K</td>
<td align="right">289</td>
<td align="right">508</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$5.4</td>
<td>$5.2</td>
<td>$5.2</td>
<td>$139.00</td>
<td>$52.0K</td>
<td align="right">0</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$18.1</td>
<td>$17.3</td>
<td>$18.1</td>
<td>$130.00</td>
<td>$36.2K</td>
<td align="right">17</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Biogen</h3>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
In light of the recent options history for Biogen, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Biogen</h3>
<ul>
<li>Trading volume stands at 1,318,628, with BIIB's price down by -2.5%, positioned at $138.97.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Expert Opinions on Biogen</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on Biogen, maintaining a target price of $160. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biogen with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Biogen's Options Frenzy: What You Need to Know

Biotech giant Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) is scheduled to report fourth-quarter earnings on 12 February.
The Wall Street forecasts fourth-quarter adjusted EPS of $3.35 and sales of $2.40 billion, while fiscal year 2024 adjusted EPS is expected to be $16.34 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $9.64 billion</a>.
January 2025 had been an eventful month for Biogen. Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) announced that its Board of Directors initiated a process to explore strategic alternatives and rejected the unsolicited, nonbinding proposal it received from Biogen for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43232552/sage-therapeutics-board-of-directors-initiates-review-of-strategic-alternatives-and-rejects-biogen" rel="noreferrer noopener">$7.22 per share</a>.
In January, the FDA approved the Supplemental marketing application for lecanemab-irmb (Leqembi) intravenous (IV) maintenance dosing once <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43219641/fda-approves-leqembi-lecanemab-irmb-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-di" rel="noreferrer noopener">every four weeks</a>.
Leqembi is indicated for Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease. After 18 months of once every two weeks initiation phase, a transition to the maintenance dosing regimen of 10 mg/kg once every four weeks may be considered or the regimen of 10 mg/kg once every two weeks may be continued.
The FDA and the European Medicines Agency accepted to review supplemental marketing applications seeking approval for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA).
The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and a higher maintenance regimen, 28 mg, every 4 months, compared to the approved <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43156759/fda-and-ema-accept-applications-for-higher-dose-regimen-of-nusinersen-in-sma" rel="noreferrer noopener">nusinersen regimen (Spinraza)</a>.&nbsp;
The European Commission asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024, whether this may require an update of the opinion, and whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. These will be discussed at the CHMP <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43380334/update-on-regulatory-review-of-lecanemab-for-early-alzheimers-disease-in-the-european-union" rel="noreferrer noopener">meeting in February 2025</a>.
Investors are focused on Biogen's growth strategies. This includes expanding its pipeline, pursuing external business development, or leveraging new opportunities to counter declining revenue in the latter&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42957657/biogens-push-for-sage-therapeutics-could-strengthen-its-neurology-strategy-analysts-say" rel="noreferrer noopener">half of the decade</a>.
In December, Jefferies&nbsp;downgraded&nbsp;Biogen, citing the&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42397286/biogen-downgraded-on-pipeline-setbacks-and-leqembi-sales-slowdown" rel="noreferrer noopener">company's tough setup</a>.
Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.
Challenges like PET scan reimbursement, slow protocol updates at major hospital networks, and identifying eligible patients continue to hinder adoption.
Price Action: BIIB stock is down 2.61% at $138.81 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43633084/communications-firm-anterix-initiates-strategic-review-with-morgan-stanley-stock-surges" target="_blank" rel="noreferrer noopener">Communications Firm Anterix Initiates Strategic Review With Morgan Stanley, Stock Surges</a></li>
</ul>

Previews

What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?

<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Sage Therapeutics, Inc. NASDAQ: SAGE) is officially exploring "strategic alternatives" to make shareholders happy. The process includes anything from a possible business combination to a full-on sale. Who&#8217;s interested? That would be Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), which submitted an unsolicited offer Sage rejected. Cambridge, Massachusetts-based Sage is known for its ZURZUVAE treatment for women with PPD. Goldman Sachs is providing financial advice and Skadden, Arps, Slate, Meagher &amp; Flom LLP oversees legal matters. </li>
<li>Silvus Technologies, a Los Angeles-based mobile telecom owned by TJC, hired Morgan Stanley to explore a sale or initial public offering. TJC could seek a valuation of as much as $5 billion for Silvus, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-30/tjc-is-said-to-weigh-sale-ipo-of-radio-tech-provider-silvus">reported</a> citing sources. TJC, aka The Jordan Company purchased Silvus in December 2019. </li>
<li>Allakos Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) is shutting down its AK006 program, leading to a major downsizing — about 75% of the company will be laid off. The biotech plans to keep around 15 employees to explore strategic alternatives, which CEO Robert Alexander described as "the usual things," according <a href="https://www.fiercebiotech.com/biotech/allakos-axes-program-lays-75-staff-and-seeks-strategic-alternatives-after-phase-1-flop">to</a> Fierce Biotech. The move will significantly deplete Allakos' cash reserves, which stood at $81 million at the end of last year. The company expects to spend $34 million to $38 million on severance and restructuring costs, leaving it with just $35 million to $40 million in reserves by mid-year. The pressure is on to find a new strategic direction quickly.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>YouTube star Jimmy Donaldson (aka MrBeast) has secured more than <a href="https://www.benzinga.com/25/01/43325891/backed-by-youtube-king-mrbeast-group-of-american-investors-including-roblox-ceo-lock-in-over-20-billion-for-tiktok-takeover-but-they-have-not-heard-back-directly-from-bytedance">$20 billion</a> for a TikTok offer. An investor group, led by tech entrepreneur Jesse Tinsley, includes Roblox Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) CEO David Baszucki and Anchorage Digital CEO Nathan McCauley as investors. Tinsley <a href="https://www.bloomberg.com/news/articles/2025-01-29/tiktok-bidders-to-offer-significantly-more-than-20-billion?sref=KkPzpZvz">told</a> Bloomberg that their offer is &#8220;significantly higher&#8221; than a competing $20 billion bid. Whether Tinsley was referring to the <a href="https://www.benzinga.com/general/entertainment/25/01/42834240/kevin-oleary-joins-the-peoples-bid-for-tiktok-as-pending-ban-looms">Project Liberty bid</a> by former Los Angeles Dodgers owner Frank McCourt and &#8220;Shark Tank&#8221; star Kevin O'Leary is unclear. Also uncertain is whether Microsoft was seriously making a bid, <a href="https://www.benzinga.com/25/01/43260646/microsoft-eyes-tiktok-us-deal-as-trump-confirms-acquisition-talks-are-underway">as indicated by President Trump</a>.</li>
</ul>
<ul>
<li>Hewlett Packard Enterprise&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) $14 billion purchase of Juniper Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) hit a roadblock. The Department of Justice is suing the tech company in what marks the first antitrust action of Trump's second term. The deal would result in Cisco Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and the combined HPE-Juniper entity controlling 70% of the wireless networking industry, regulators <a href="https://www.wsj.com/politics/policy/justice-department-sues-to-block-hewlett-packard-enterprises-bid-for-juniper-networks-99af47ac?mod=deals_news_article_pos1&amp;utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axiosprorata&amp;stream=top">said</a>. The merger, which was announced last January, has already received U.K. and EU regulatory approvals. </li>
<li>President Vladimir Putin signed a decree allowing Goldman Sachs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) to sell its Russia subsidiary to Balchug Capital.<a href="https://link.axios.com/click/38421266.59136/aHR0cHM6Ly9heGlvcy5saW5rLzQweWRrelk_dXRtX3NvdXJjZT1uZXdzbGV0dGVyJnV0bV9tZWRpdW09ZW1haWwmdXRtX2NhbXBhaWduPW5ld3NsZXR0ZXJfYXhpb3Nwcm9yYXRhJnN0cmVhbT10b3A/5841ec813f92a47b9bba9e4dBd37e415e" target="_blank" rel="noreferrer noopener"> </a>The deal makes the U.S. bank one of the few Western banks to fully exit the country, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-31/putin-allows-goldman-sachs-to-sell-its-business-in-russia?srnd=phx-deals">reports</a>.</li>
</ul>
<ul>
<li>Nippon Steel (TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:5401#TYO">5401</a>) launched a $456 million tender offer for the remainder of its subsidiary Sanyo Special Steel (TYO:<a class="ticker" href="https://www.benzinga.com/stock/TYO:5481#TYO">5481</a>), representing a 37% premium.</li>
</ul>
<ul>
<li>Outbrain Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) <a href="https://www.wsj.com/business/deals/outbrain-teads-1-billion-merger-deal-cleared-by-u-k-antitrust-regulator-dbc95d74?mod=deals_news_article_pos1">received</a> U.K. antitrust approval for its $1-billion acquisition of Dutch digital advertising platform from Altice, according to the Wall Street Journal.</li>
</ul>
<ul>
<li>Welltower Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) <a href="https://welltower.com/investors/press-release-details/?id=27351#xd_co_f=YTg5NDI3NDMtNjI0Yy00MWUzLTllMDctNDQwMjQxZTliMTg3~">acquired</a> NorthStar Healthcare Income, a New York-based real estate investment trust focused on senior housing, for $900 million.</li>
</ul>
<ul>
<li>Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>), an automation technology provider, has agreed to acquire the remaining shares it doesn't own of software supplier AspenTech for $265 per share in an all-cash tender offer. The minority stake being now acquired is <a href="https://www.benzinga.com/news/large-cap/25/01/43229951/emerson-electric-to-buy-out-aspentech-minority-stake-in-7-2-billion-cash-deal">valued at $7.2 billion</a>.</li>
</ul>
<h2 class="wp-block-heading">Off The Block</h2>
<ul>
<li>General Mills Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) completed the $2.1 billion sale of its U.S. and Canadian yogurt units to French dairies Groupe Lactalis and Sodiaal.</li>
</ul>
<h2 class="wp-block-heading">Bankruptcy Block</h2>
<ul>
<li>Spirit Airlines rejected a $400 million merger proposal from Frontier Group Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>). The offer wasn&#8217;t high enough, the bankrupt air carrier said. Spirit, considered the biggest U.S. budget airline, filed a Chapter 11 <a href="https://www.benzinga.com/24/11/42032477/spirit-airlines-eyes-financial-stability-with-chapter-11-filing-and-equity-injection">bankruptcy petition in November</a>.</li>
</ul>
For last week&#8217;s <a href="https://www.benzinga.com/news/asset-sales/25/01/43216373/deal-dispatch-lovely-day-to-sell-guinness-plus-23andme-to-rid-lineage-of-lemonaid">Deal Dispatch, click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/01/43396354/inflation-rises-again-may-be-end-of-the-road-for-interest-rate-cuts-expert-says">Inflation Rises Again: May Be &#8216;End Of The Road&#8217; For Interest Rate Cuts, Expert Says</a></li>
</ul>

Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok

In November 2024, a positive opinion was received from the Committee for Medicinal Products for Human Use (CHMP) recommending approval of lecanemab.1 As part of its decision-making process, the European Commission (EC) has asked the CHMP to consider information on the safety of lecanemab that became available after the adoption of the CHMP opinion in November 2024 and whether this may require an update of the opinion, and to consider whether the wording of the risk minimization measures in the opinion is clear enough to ensure correct implementation. These will be discussed at the CHMP meeting in February 2025.
 &nbsp;

Biogen And Eisai Reveals Update On Ongoing Regulatory Review Of Marketing Authorization Application For lecanemab As Treatment For Early AD In European Union

Across the recent three months, 18 analysts have shared their insights on Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of $300.00, and a low estimate of $138.00. A 16.73% drop is evident in the current average compared to the previous average price target of $257.94. 
<img src="https://www.benzinga.com/files/images/story/2025/1738072821_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Biogen among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$165.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$138.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$164.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$178.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$180.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Salim Syed</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$207.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$294.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$204.00</td>
<td>$285.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biogen. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biogen compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Biogen's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Biogen's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BIIB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biogen analyst ratings.</a>
<h2>Delving into Biogen's Background</h2>
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
<h3>Biogen's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining Biogen's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -2.55% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.76%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Biogen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Biogen's ROA excels beyond industry benchmarks, reaching 1.41%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.41.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Biogen: 18 Analysts Share Their Views

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Neutral and lowers the price target from $190 to $160.

Citigroup Maintains Neutral on Biogen, Lowers Price Target to $160

Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders
The Company Remains Focused on the Goal of Establishing ZURZUVAE as the Standard of Care for Women with Postpartum Depression

Sage Therapeutics Initiates Review Of Strategic Alternatives; Rejects Biogen's Unsolicited Acquisition Proposal

<ul>
<li>Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment</li>
<li>Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy</li>
</ul>

ESAIY

Reported Sunday, Eisai And Biogen Achieve FDA Approval For LEQEMBI IV Maintenance Dosing, Reducing Treatment Frequency For Early Alzheimer's Patients

Wall Street Lunch: Boom Goes The CPI

Biogen targets $15.25-$16.25 EPS for 2025 amid LEQEMBI growth and cost savings

Stifel analyst Paul Matteis lowered the firm's price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The shares ar...

Biogen price target lowered to $144 from $175 at Stifel

S&P finishes lower in mixed trade after Wall Street weighs hot January inflation data

Goldman Sachs lowered the firm's price target on Biogen (BIIB) to $245 from $281 but keeps a Buy rating on the shares. The firm cites the company's...

Biogen price target lowered to $245 from $281 at Goldman Sachs

Biogen Inc. ( ($BIIB) ) has released its Q4 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is...

Biogen Inc. Reports 2024 Earnings and 2025 Outlook

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $...

Cautious Outlook for Biogen Amid Revenue Decline and Market Challenges

Wells Fargo lowered the firm's price target on Biogen (BIIB) to $140 from $165 and keeps an Equal Weight rating on the shares. The firm notes Bioge...

Biogen price target lowered to $140 from $165 at Wells Fargo

Citi lowered the firm's price target on Biogen (BIIB) to $145 from $160 and keeps a Neutral rating on the shares post the Q4 report. The company's ...

Biogen price target lowered to $145 from $160 at Citi

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $225.00. The comp...

RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)

INTC

Press Releases

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA

FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen's Unsolicited Acquisition Proposal

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

AGIO

IONS

PRAX

Comments

Biogen

매도 수량

Biogen (NASDAQ:BIIB) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌